Equibles does not estimate personal net worth.
Get an email with a short summary when Agios Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AGIO alertsAgios Pharmaceuticals, Inc. reported in an 8-K filed December 6, 2022 that Tsveta Milanova was appointed Chief Commercial Officer, effective January 3, 2023. The proxy statement of Agios Pharmaceuticals, Inc. reports total compensation of $2,453,418 for Tsveta Milanova in fiscal 2024, including a base salary of $525,300. Disclosed compensation is on record for 4 fiscal years. Tsveta Milanova has spoken on 2 earnings calls and 6 other investor events across 1 company, most recently for Agios Pharmaceuticals, Inc. on September 9, 2026. Agios Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Agios Pharmaceuticals, Inc. includes Brian Goff (CEO and Board Member), Jacqualyn Fouse (CEO and Board Member), David P. Schenkein (Chairman) and 7 others.
“the Board of Directors (the "Board") of the Company appointed Tsveta Milanova as the Company's Chief Commercial Officer, effective as of January 3, 2023 (the "Effective Date").”
“With six months of launch experience now behind us, we are encouraged by the underlying drivers of performance. What we have seen so far continues to reinforce our confidence in the long-term of spysmy opportunity in Thalassemia.”
“With six months of launch experience now behind us, we are encouraged by the underlying drivers of performance. What we have seen so far continues to reinforce our confidence in the long-term of spysmy opportunity in Thalassemia.”
“Thank you, Amar, and thank you, Dr. Anderson and Dr. Otaga, for sharing your perspectives on MetaPivot and the sickle cell disease landscape.”
“Thank you, Amar, and thank you, Dr. Anderson and Dr. Otaga, for sharing your perspectives on MetaPivot and the sickle cell disease landscape.”
“So as Sarah mentioned, commercially we'll be ready to execute irrespective of the brand name and the label.”
Proxy statement
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Commercial Officer | $525,300 | $2,453,418 |
| 2023 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Commercial Officer | $507,875 | $3,733,273 |
| 2022 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Commercial Officer | — | — |
| 2021 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Commercial Officer | — | — |
